ResMed CEO Michael J. Farrell Sells 3,200 Shares (RMD)
ResMed (NYSE:RMD) CEO Michael J. Farrell unloaded 3,200 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The shares were sold at an average price of $53.20, for a total transaction of $170,240.00. Following the transaction, the chief executive officer now directly owns 106,655 shares in the company, valued at approximately $5,674,046. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
RMD has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of ResMed in a research note on Wednesday, June 11th. They now have a $55.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. upgraded shares of ResMed from a “neutral” rating to an “overweight” rating in a research note on Tuesday, June 10th. Finally, analysts at Northland Securities downgraded shares of ResMed from a “market perform” rating to an “underperform” rating in a research note on Tuesday, May 27th. They now have a $40.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $46.90.
Shares of ResMed (NYSE:RMD) traded up 0.70% on Wednesday, hitting $53.06. 273,531 shares of the company’s stock traded hands. ResMed has a 1-year low of $41.52 and a 1-year high of $57.34. The stock’s 50-day moving average is $50.84 and its 200-day moving average is $46.9. The company has a market cap of $7.446 billion and a P/E ratio of 23.12.
ResMed (NYSE:RMD) last released its earnings data on Wednesday, April 23rd. The company reported $0.63 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter in the prior year, the company posted $0.58 earnings per share. The company’s quarterly revenue was up 3.7% on a year-over-year basis. On average, analysts predict that ResMed will post $2.49 earnings per share for the current fiscal year.
ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.